EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma

Jing Wang, Yanan Wang, Hanyu Pan, Lin Zhao, Xinyi Yang, Zhiming Liang, Xiaoting Shen, Jing Zhang, Jinlong Yang, Yuqi Zhu, Jingna Xun, Yue Liang und 4 weitere

International Journal of Molecular Sciences · 12.03.2023 · 24 (6) · 5424

DOI: 10.3390/ijms24065424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2023. Verfasst von Jing Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, Science and Technology Innovation Plan of the Shanghai Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cells, a therapeutic agent for solid tumors, are not completely effective due to a lack of infiltration of T cells into the tumor site and immunity caused by Programmed Death Receptor 1(PD1). Here, an epidermal growth factor receptor (EGFR) CAR-T cell was engineered to express the chemokine receptor CCR6 and secrete PD1 blocking Single-chain antibody fragment (scFv) E27 to enhance their anti-tumor effects. The findings showed that CCR6 enhanced the migration of EGFR CAR-E27-CCR6 T cells in vitro by the Transwell migration assay. When incubated with tumor cells, EGFR CAR-E27-CCR6 T cells specifically exerted potent cytotoxicity and produced high levels of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and interferon-γ (IFN-γ). A non-small cell lung carcinoma (NSCLC) cell line-derived xenograft model was constructed by implanting modified A549 cell lines into immunodeficient NOD.PrkdcscidIl2rgem1/Smoc (NSG) mice. In comparison with traditional EGFR CAR-T cells, live imaging indicated that EGFR CAR-E27-CCR6 T cells displayed superior anti-tumor function. In addition, the histopathological examination of mouse organs showed no obvious organic damage. Our findings confirmed that PD1 blocking and CCR6 can enhance the anti-tumor function of EGFR CAR-T cells in an NSCLC xenograft model, providing an effective treatment strategy to improve the efficacy of CAR-T in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, Chimeric AntigenAnimalsHumansMiceCell Line, TumorErbB ReceptorsImmunotherapy, AdoptiveMice, Inbred NODReceptors, CCR6Receptors, ChemokineXenograft Model Antitumor AssaysProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

CAR T cell therapyCCR6EGFRNSCLCPD1checkpointchemokinemigration

Substanzen

CCR6 protein, humanCCR6 protein, mouseErbB ReceptorsReceptors, CCR6Receptors, ChemokineReceptors, Chimeric AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200082, China.
  • School of Life Sciences, Fudan University, Shanghai 200082, China.

Förderung

  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • Science and Technology Innovation Plan of the Shanghai Science and Technology Commission

Zitieren

APA

Wang, J., Wang, Y., Pan, H., Zhao, L., Yang, X., Liang, Z., Shen, X., Zhang, J., Yang, J., Zhu, Y., Xun, J., Liang, Y., Lin, Q., Liang, H., Li, M., & Zhu, H. (2023). Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 24(6), 5424. https://doi.org/10.3390/ijms24065424

Vancouver

Wang J, Wang Y, Pan H, Zhao L, Yang X, Liang Z, et al. Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences. 2023;24(6):5424. doi:10.3390/ijms24065424

BibTeX
@article{Wang2023,
  author = {Wang, Jing and Wang, Yanan and Pan, Hanyu and Zhao, Lin and Yang, Xinyi and Liang, Zhiming and Shen, Xiaoting and Zhang, Jing and Yang, Jinlong and Zhu, Yuqi and Xun, Jingna and Liang, Yue and Lin, Qinru and Liang, Huitong and Li, Min and Zhu, Huanzhang},
  title = {Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5424},
  doi = {10.3390/ijms24065424}
}
Kostenlos starten →